Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2766056 | 0.85 | KDM4E (0.37) | ALDH1A1MAPTKDM4ETP53SMN1; SMN2 | |
| SCHEMBL2765441 | 0.75 | KMT2A (0.40) | POLBKMT2A | |
| SCHEMBL2766552 | 0.69 | P2RY6 (0.45) | ALDH1A1P2RY6MAPTKDM4EPOLB | |
| Butadiene SCHEMBL6472795 | 0.68 | MAPT (0.52) | ALDH1A1P2RY6MAPTKDM4EPOLB | |
| SCHEMBL2766012 | 0.68 | P2RY6 (0.47) | ALDH1A1P2RY6MAPTKDM4EPOLB | |
| SCHEMBL2765651 | 0.67 | MAPK13 (0.32) | — | |
| SCHEMBL2765500 | 0.65 | KDM4E (0.33) | ALDH1A1KDM4E | |
| SCHEMBL2766048 | 0.65 | — | — | |
| SCHEMBL10608666 | 0.63 | ALDH1A1 (0.56) | ALDH1A1MAPTKDM4EPOLBSMN1; SMN2 | |
| SCHEMBL27890734 | 0.63 | TP53 (0.47) | ALDH1A1P2RY6MAPTKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881802-B2 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-04-19 | — | — | US | disclosed |
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1266911-A1 | Catalyst for addition polymerization and process for producing an addition polymer | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032743-A1 | Catalyst for addition polymerization and process for producing an addition polymer | BRAP, MCM4, BOLA2; BOLA2B | ALDH1A1 3572/4885P2RY6 2014/4885MAPT 749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.